Tocofersolan
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Tocofersolan: From Undetermined Original Indication to Amenorrhea (Disease)
One-Sentence Summary
The original indication and mechanism of action for Tocofersolan (DrugBank ID DB11635) are not recorded in the available evidence pack, though the drug’s own repurposing rationale identifies it as a vitamin E precursor (TPGS, D-alpha-tocopheryl polyethylene glycol succinate). The TxGNN model predicts a possible association with Amenorrhea (disease), but this pairing is currently supported by zero clinical trials and zero publications, making it a pure computational prediction (TxGNN score 99.31%) with no biological rationale offered by the model itself.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available (data gap in evidence pack) |
| Predicted New Indication | Amenorrhea (disease) |
| TxGNN Prediction Score | 99.31% |
| Evidence Level | L5 |
| UK Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data for Tocofersolan is not available in this evidence pack (flagged as a High-severity data gap, DG002). The only mechanistic context provided comes from the model’s own rationale text, which identifies Tocofersolan as a vitamin E precursor (TPGS). No original indication is recorded at all (DG001, Blocking severity, also missing UK/TFDA labelling data), so it is not possible to assess pharmacological continuity between an established use and the predicted indication.
For the top-ranked prediction, Amenorrhea (disease), the evidence pack’s own rationale is explicit that no known mechanistic link exists between Tocofersolan and this condition, and that the pairing is a purely statistical output of the TxGNN knowledge graph rather than a hypothesis grounded in pharmacology.
A further caution: two of the ten ranked predictions in this evidence pack (rank 3, “malignant catarrh”, and rank 4, “infectious bovine rhinotracheitis”) are veterinary/bovine diseases with no relevance to human therapeutics. Their presence suggests a possible entity-mapping error in the underlying disease vocabulary, and this should lower confidence in the overall prediction set for this drug pending vocabulary review.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
UK Market Information
Tocofersolan currently has no marketing authorisation on record for the UK (market status: not marketed, 0 authorisations). No product, dosage form or approved indication data is available.
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
Conclusion and Next Steps
Decision: Hold
Rationale: This candidate is at the earliest possible evaluation stage (S0/L5): no original indication, MOA, or UK labelling data are on file, no clinical trials or literature support the top prediction, and the drug has no UK marketing authorisation. The presence of veterinary-disease entities elsewhere in the prediction list also raises data-quality concerns about the underlying knowledge graph mapping for this drug.
To proceed, the following is needed:
- Resolve Blocking data gap DG001: obtain TFDA/SmPC labelling (warnings, contraindications) before any safety screening (S1) can begin
- Resolve High-severity data gap DG002: confirm mechanism of action via DrugBank API to support or refute mechanistic plausibility
- Original indication history for Tocofersolan, to establish a baseline for assessing repurposing rationale
- Independent literature/clinical trial search specifically for Tocofersolan and amenorrhea, since none were captured by current collectors
- Verification of the disease vocabulary mapping used by TxGNN for this drug, given the presence of non-human (veterinary) disease entities in the ranked output
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.